Literature DB >> 1698564

Role of natural killer cells in the modulation of primary antibody production by purine nucleosides and their analogs.

T Priebe1, L Ruiz, J A Nelson.   

Abstract

Previous results from this laboratory demonstrated that treatment of mice with the adenosine analog tubercidin (Tub) reduced natural killer (NK) cell activity while stimulating antibody production whereas the deoxyadenosine analog, 2-fluoroadenine arabinoside-5'-monophosphate (FaraAMP), produced opposite effects; i.e., it stimulated NK cell activity at doses that inhibited antibody formation (Cancer Res. 48, 4799, 1988). Since NK cells have been reported to play a suppressor role in immunoglobulin induction, it was hypothesized that the actions of Tub and FaraAMP on antibody production occurred secondary to their opposing effects on NK cells. To test this hypothesis, abilities of these nucleoside analogs to modulate primary antibody response to sheep red blood cells were evaluated in a C57BL/6 mutant mouse lacking NK cell activity (the beige mutation. C57BL/6-bg/bg). As previously found with C3H/He mice. NK cell activity was inhibited (Tub, doses 2-6 mg/kg/day for 3 days) or stimulated (FaraAMP, doses 75-250 mg/kg/day for 3 days) in heterozygous mice C57BL/6-bg/+. In support of the hypothesis, these nucleosides had no effect on primary antibody formation in the homozygous mutant mice at doses that clearly stimulated (Tub) or inhibited (FaraAMP) this immune response in heterozygous C57BL/6-bg/+ animals. This results was corroborated in C57BL/6 wild-type mice by abrogation of NK cell activity using a monoclonal antibody to the NK cell surface glycophisingolipid, ganglio-n-tetraosylceramide. We conclude that under the conditions of drug administration, modulation of primary antibody formation by Tub and FaraAMP in mice occurs indirectly via NK cells. Similar experiments using the potent ADA inhibitor, deoxycoformycin, indicated that its enhancement of primary antibody formation is independent of NK cell activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698564     DOI: 10.1016/0008-8749(90)90291-x

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

Review 1.  Hirschsprung's disease: clinical and experimental observations.

Authors:  P Puri
Journal:  World J Surg       Date:  1993 May-Jun       Impact factor: 3.352

2.  Mucosal immune defence mechanisms in enterocolitis complicating Hirschsprung's disease.

Authors:  A Imamura; P Puri; D S O'Briain; D J Reen
Journal:  Gut       Date:  1992-06       Impact factor: 23.059

3.  Intracellular disposition of fludarabine triphosphate in human natural killer cells.

Authors:  Erica L Woodahl; Joanne Wang; Shelly Heimfeld; Brenda M Sandmaier; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2008-09-10       Impact factor: 3.333

4.  Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.

Authors:  L E Robertson; A W Denny; Y O Huh; W Plunkett; M J Keating; J A Nelson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 5.  Potential immunological action of purine nucleoside analogues.

Authors:  G Dighiero
Journal:  Drugs       Date:  1994       Impact factor: 9.546

6.  Search for adenosine A2A spare receptors on peripheral human lymphocytes.

Authors:  Laurent Jacquin; Frédéric Franceschi; Youlet By; Josée-Martine Durand-Gorde; Jocelyne Condo; Jean-Claude Deharo; Pierre Michelet; Emmanuel Fenouillet; Régis Guieu; Jean Ruf
Journal:  FEBS Open Bio       Date:  2012-11-17       Impact factor: 2.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.